Did everyone see the NVLX news yesterday? Nuvilex
Post# of 1086
Posted On: 02/20/2014 8:39:35 AM
Did everyone see the NVLX news yesterday? Nuvilex is getting closer to clinical phase-III trials on it's newly developed pancreatic cancer treatment.
The company's advanced pancreatic cancer treatment that combines the Cell-in-a-Box technology with ifosfamide has provided better results than both gemcitabine alone and the Abraxane-gemcitabine combination. Those results included an increase of about 4 months in median survival time over gemcitabine alone versus the 1.8 months seen with the Abraxane-gemcitabine combination. The results also included a 100% increase in the one-year survival rate as compared to gemcitabine versus a 59% increase for the Abraxane-gemcitabine combination. The results obtained with Nuvilex's treatment are even more noteworthy given that only one-third of the dose of ifosfamide normally used to treat other types of cancer was used in the Phase II pancreatic cancer trials.
(0)
(0)